ARTICLE | Clinical News
RK-0202: Phase Ib
March 12, 2001 8:00 AM UTC
The joint venture between RxKinetix and ELN will begin a Phase Ib trial of RK-0202, which combines RxKinetix's ProGelz with an undisclosed, marketed small molecule that has antioxidant properties. ...